Immix biopharma presents positive nxc-201 clinical data at 66th american society of hematology (ash) annual meeting in 16 relapsed/refractory al amyloidosis patients

75% (12/16) complete response rate observed in relapsed/refractory al amyloidosis patients with median 4 prior lines of therapy data will be presented on monday, december 9, 2024 at 4:00 pm pt los angeles, nov. 25, 2024 (globe newswire) -- immix biopharma, inc. (“immixbio”, “company”, “we” or “us” or ”immx”), a clinical-stage biopharmaceutical company developing cell therapies for al amyloidosis and select immune-mediated diseases, today announced that additional nexicart-1 nxc-201 clinical data in relapsed/refractory al amyloidosis has been selected for oral presentation at the upcoming 66th american society of hematology (ash) annual meeting to be held in san diego, california, december 7-10, 2024. “nxc-201 is the only car-t in development for relapsed/refractory al amyloidosis patients,” said ilya rachman, md phd, chief executive officer of immix biopharma.
ASH Ratings Summary
ASH Quant Ranking